Filing Flows › Edwards Lifesciences (EW) › Capital expenditures
Edwards Lifesciences (EW) capital expenditures by quarter
Edwards Lifesciences' capital expenditures were $63.6M in Q3 2026 (third quarter 2026), -5% from Q2 2026. Over the last 7 quarters it ranged from $49.3M (Q2 2025) to $97.4M (Q4 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $63.6M | -5% | +11% |
| Q2 2026 | $66.9M | +3% | +36% |
| Q1 2026 | $64.9M | -33% | +16% |
| Q4 2025 | $97.4M | +69% | — |
| Q3 2025 | $57.5M | +17% | — |
| Q2 2025 | $49.3M | -12% | — |
| Q1 2025 | $56.0M | — | — |
Q3 2026 at a glance
Edwards Lifesciences, Q3 2026: revenue $1.7B (+10% year over year), operating margin 17.4%, net earnings $308M, operating cash flow $570M. The chart follows the revenue to costs, profit and cash.
Questions
What is Edwards Lifesciences' capital expenditures?
Edwards Lifesciences' capital expenditures were $63.6M in Q3 2026 (third quarter 2026), -5% from Q2 2026.
How has Edwards Lifesciences' capital expenditures changed?
Over the last 7 quarters it ranged from $49.3M (Q2 2025) to $97.4M (Q4 2025).